Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tests best antibiotic for superbug infections

NCT ID NCT06738771

Disease control Sponsor: Centre Hospitalier Régional d'Orléans Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at 600 adults with infections caused by a hard-to-treat bacteria called Pseudomonas aeruginosa. Researchers will compare newer and older antibiotics to see which works best to cure the infection. The goal is to find the most effective treatment for these dangerous superbug infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 600 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2025

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Prospective multicenter cohort

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * All patients aged 18 or over and requiring intravenous definite antimicrobial therapy for a DTR P. aeruginosa infection Exclusion Criteria: * Cystic fibrosis * P. aeruginosa DTR colonization or P. aeruginosa DTR infection not requiring definitive intravenous antibiotic therapy * Protected person (under guardianship or curatorship) * Persons under court protection * Persons deprived of liberty * Opposition expressed for participation in the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Antibacterial agents are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Pseudomonas aeruginosa infectious disease Pseudomonas infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Antibacterial agents Beta-lactam antibiotics Drug resistance, multiple, bacterial Prognosis Pseudomonas aeruginosa Pseudomonas infections

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    48 sites in 2 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CH Argenteuil

    NOT_YET_RECRUITING

    Argenteuil, France

  • CH Bayonne

    NOT_YET_RECRUITING

    Bayonne, France

  • CH Bethune

    NOT_YET_RECRUITING

    Béthune, France

  • CH Bourgoin-Jallieu

    NOT_YET_RECRUITING

    Bourgoin, France

  • CH Haguenau

    NOT_YET_RECRUITING

    Haguenau, France

  • CH Métropole Savoie

    NOT_YET_RECRUITING

    Chambéry, France

  • CH PAU

    NOT_YET_RECRUITING

    Pau, France

  • CH Perpignan

    NOT_YET_RECRUITING

    Perpignan, France

  • CH Saint-Lô

    NOT_YET_RECRUITING

    Saint-Lô, France

  • CH Sud Essone

    NOT_YET_RECRUITING

    Étampes, France

  • CH Tourcoing

    NOT_YET_RECRUITING

    Tourcoing, France

  • CH Vannes

    NOT_YET_RECRUITING

    Vannes, France

  • CHD Vendée

    RECRUITING

    La Roche-sur-Yon, France

  • CHI Créteil

    NOT_YET_RECRUITING

    Créteil, France

  • CHI Elbeuf Louviers

    NOT_YET_RECRUITING

    Elbeuf, France

  • CHRU Nancy

    RECRUITING

    Nancy, France

  • CHRU Strasbourg Haute Pierre

    NOT_YET_RECRUITING

    Strasbourg, France

  • CHU Amiens

    NOT_YET_RECRUITING

    Amiens, France

  • CHU Avicenne

    NOT_YET_RECRUITING

    Bobigny, France

  • CHU Clermont Ferrand

    NOT_YET_RECRUITING

    Clermont-Ferrand, France

  • CHU Grenoble

    NOT_YET_RECRUITING

    Grenoble, France

  • CHU Henri Mondor

    NOT_YET_RECRUITING

    Créteil, France

  • CHU La Réunion

    NOT_YET_RECRUITING

    Saint-Denis, Reunion

  • CHU Limoges

    NOT_YET_RECRUITING

    Limoges, France

  • CHU Lyon

    NOT_YET_RECRUITING

    Lyon, France

  • CHU Lyon Sud

    NOT_YET_RECRUITING

    Lyon, France

  • CHU Montpellier

    NOT_YET_RECRUITING

    Montpellier, France

  • CHU Reims

    NOT_YET_RECRUITING

    Reims, France

  • CHU Strasbourg

    NOT_YET_RECRUITING

    Strasbourg, France

  • CHU de BESANCON

    NOT_YET_RECRUITING

    Besançon, France

  • CHU de Nice

    NOT_YET_RECRUITING

    Nice, France

  • CHY Lyon

    NOT_YET_RECRUITING

    Lyon, France

  • Centre Hospitalier Universitaire d'Orléans

    RECRUITING

    Orléans, France

  • Centre Hospitalier de Périgueux

    NOT_YET_RECRUITING

    Périgueux, France

  • Ch de Chartres

    NOT_YET_RECRUITING

    Chartres, France

  • Chu de Nantes

    NOT_YET_RECRUITING

    Nantes, France

  • Hopital Bicetre

    NOT_YET_RECRUITING

    Le Kremlin-Bicêtre, France

  • Hopital Bichat

    RECRUITING

    Paris, France

  • Hopital Cochin

    NOT_YET_RECRUITING

    Paris, France

  • Hopital Foch

    NOT_YET_RECRUITING

    Suresnes, France

  • Hopital LARIBOISIERE

    NOT_YET_RECRUITING

    Paris, France

  • Hopital Pitie Salpetriere

    NOT_YET_RECRUITING

    Paris, France

  • Hopital Raymond Poincaré

    NOT_YET_RECRUITING

    Garches, France

  • Hopital Saint-Antoine

    NOT_YET_RECRUITING

    Paris, France

  • Hopital Saint-Joseph Saint Luc

    NOT_YET_RECRUITING

    Lyon, France

  • Hôpital Européen Georges Pompidou

    NOT_YET_RECRUITING

    Paris, France

  • Hôpital Nord-Ouest de Villefranche sur Saone

    NOT_YET_RECRUITING

    Villefranche-sur-Saône, France

  • Hôpital Saint-Louis

    NOT_YET_RECRUITING

    Paris, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.